Skip to main content
Top
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Case report

Tuberculous pneumonia-induced severe ARDS complicated with DIC in a female child: a case of successful treatment

Authors: Dong Tien Ngo, Phuc Huu Phan, Shoji Kawachi, Noriko Nakajima, Naoyuki Hirata, Akira Ainai, Thuy Thi Bich Phung, Dien Minh Tran, Hai Thanh Le

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

Tuberculous (TB) pneumonia can induce acute respiratory distress syndrome (ARDS). Although TB pneumonia is one of the causes of disease and death among children worldwide, the literature on TB pneumonia-induced ARDS is limited. We report herein on the successful treatment of a two-year-old female child with TB pneumonia-induced severe ARDS complicated with disseminated intravascular coagulation (DIC).

Case presentation

A two-year-old Vietnamese female child with sustained fever and cough for 20 days was transferred to our hospital. She had severe dyspnea and a chest X-ray showed bilateral infiltration without findings of heart failure. After tracheal intubation, her oxygenation index (OI) and PaO2/FiO2 (PF) ratio were 29 and 60 mmHg, respectively. Mycobacterium tuberculosis was detected by real-time polymerase chain reaction (rPCR) assay of tracheal lavage fluid. She was diagnosed as having severe ARDS that developed from TB pneumonia. Anti-tuberculous therapy and cardiopulmonary support were started. However, her respiratory condition deteriorated despite treatment with high-frequency oscillating ventilation (HFO), vasopressor support, and 1 g/kg of immunoglobulin. On the third day after admission, her International Society on Thrombosis and Hemostasis DIC score had increased to 5. Recombinant human soluble thrombomodulin (rTM) was administered to treat the DIC. After the administration of rTM was completed, OI gradually decreased, after which the mechanical ventilation mode was changed from HFO to synchronized intermittent mandatory ventilation. The DIC score also gradually decreased. Plasma levels of soluble receptor for advanced glycan end products (sRAGE) and high mobility group box 1 (HMGB-1), which are reported to be associated with ARDS severity, also decreased. In addition, inflammatory biomarkers, including interferon-gamma (IFN-γ) and interleukin-6 (IL-6), decreased after the administration of rTM. Although severe ARDS (P/F ratio ≦ 100 mmHg) continued for 19 days, the patient’s OI and P/F ratio improved gradually, and she was extubated on the 27th day after admission. The severe ARDS with DIC was successfully treated, and she was discharged from hospital on day 33 post-admission.

Conclusions

We successfully treated a female child suffering from TB pneumonia-induced severe ARDS complicated with DIC using multimodal interventions. (338/350).
Literature
1.
go back to reference Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Experience with ARDS caused by tuberculosis in a respiratory intensive care unit. Intensive Care Med. 2005;31:1284–7.CrossRefPubMed Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Experience with ARDS caused by tuberculosis in a respiratory intensive care unit. Intensive Care Med. 2005;31:1284–7.CrossRefPubMed
2.
go back to reference Sharma S, Nahar U, Das A, Radotra B, Joshi K, Varma S, Vasishta RK. Acute respiratory distress syndrome in disseminated tuberculosis: an uncommon association. Int J Tuberc Lung Dis. 2016;20:271–5.CrossRefPubMed Sharma S, Nahar U, Das A, Radotra B, Joshi K, Varma S, Vasishta RK. Acute respiratory distress syndrome in disseminated tuberculosis: an uncommon association. Int J Tuberc Lung Dis. 2016;20:271–5.CrossRefPubMed
3.
go back to reference Deng W, Yu M, Ma H, Hu LA, Chen G, Wang Y, et al. Predictors and outcome of patients with acute respiratory distress syndrome caused by miliary tuberculosis: a retrospective study in Chongquing, China. BMC Infect Dis. 2012;12:121.CrossRefPubMedPubMedCentral Deng W, Yu M, Ma H, Hu LA, Chen G, Wang Y, et al. Predictors and outcome of patients with acute respiratory distress syndrome caused by miliary tuberculosis: a retrospective study in Chongquing, China. BMC Infect Dis. 2012;12:121.CrossRefPubMedPubMedCentral
4.
go back to reference Bernard GR, Artigas A, Brigham KL, Artigas A, Brigham KL, Carlet J, et al. The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818–24.CrossRefPubMed Bernard GR, Artigas A, Brigham KL, Artigas A, Brigham KL, Carlet J, et al. The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818–24.CrossRefPubMed
5.
go back to reference Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem. 2011;44:601–4.CrossRefPubMed Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem. 2011;44:601–4.CrossRefPubMed
6.
go back to reference Beyers N, Gie RP, Schaaf HS, Van Zyl S, Talent JM, Nel ED, et al. A prospective evaluation of children under the age of 5 years living in the same household as adults with recently diagnosed pulmonary tuberculosis. Int J Tuberc Lung Dis. 1997;1:38–43.PubMed Beyers N, Gie RP, Schaaf HS, Van Zyl S, Talent JM, Nel ED, et al. A prospective evaluation of children under the age of 5 years living in the same household as adults with recently diagnosed pulmonary tuberculosis. Int J Tuberc Lung Dis. 1997;1:38–43.PubMed
7.
go back to reference Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. Lancet Infect Dis. 2008;8:498–510.CrossRefPubMed Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. Lancet Infect Dis. 2008;8:498–510.CrossRefPubMed
8.
go back to reference Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis. 2010;50:S184–94.CrossRefPubMed Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis. 2010;50:S184–94.CrossRefPubMed
9.
10.
go back to reference Doan TT, Phung TT, Pham HV, Pham SH, Nguyen LT. Effect of ganciclovir for the treatment of severe cytomegalovirus-associated pneumonia in children without a specific immunocompromised state. BMC Infect Dis. 2013;13:424.CrossRefPubMedPubMedCentral Doan TT, Phung TT, Pham HV, Pham SH, Nguyen LT. Effect of ganciclovir for the treatment of severe cytomegalovirus-associated pneumonia in children without a specific immunocompromised state. BMC Infect Dis. 2013;13:424.CrossRefPubMedPubMedCentral
11.
go back to reference Pediatric acute lung injury consensus conference group. Pediatric acute respiratory syndrome: consensus recommendations from the pediatric acute lung injury consensus conference. Pediatr Crit Care Med. 2015;16:428–39.CrossRef Pediatric acute lung injury consensus conference group. Pediatric acute respiratory syndrome: consensus recommendations from the pediatric acute lung injury consensus conference. Pediatr Crit Care Med. 2015;16:428–39.CrossRef
13.
go back to reference Saito H, Maruyama S, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.CrossRefPubMed Saito H, Maruyama S, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.CrossRefPubMed
14.
go back to reference Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T, et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med. 2013;39:644–52.CrossRefPubMedPubMedCentral Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T, et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med. 2013;39:644–52.CrossRefPubMedPubMedCentral
15.
go back to reference Yoshimura J, Yamakawa K, Ogura H, Umemura Y, Takahashi H, Morikawa M, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care. 2015;19:78.CrossRefPubMedPubMedCentral Yoshimura J, Yamakawa K, Ogura H, Umemura Y, Takahashi H, Morikawa M, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care. 2015;19:78.CrossRefPubMedPubMedCentral
16.
go back to reference Phuc PH, Dong NT, Tuan TA, Kawachi S, Nakajima N, Hirata N, et al. Successful treatment of pneumonia-induced severe ARDS complicated with DIC in two infants using recombinant human thrombomodulin. Integr Mol Med. 2017;4:1–5. Phuc PH, Dong NT, Tuan TA, Kawachi S, Nakajima N, Hirata N, et al. Successful treatment of pneumonia-induced severe ARDS complicated with DIC in two infants using recombinant human thrombomodulin. Integr Mol Med. 2017;4:1–5.
17.
go back to reference Mauri T, Masson S, Pradella A, Bellani G, Coppadoro A, Bombino M, et al. Elevated plasma and alveolar levels of soluble receptor for advanced glycation endproducts are associated with severity of lung dysfunction in ARDS patients. Tohoku J Exp Med. 2010;222:105–12.CrossRefPubMed Mauri T, Masson S, Pradella A, Bellani G, Coppadoro A, Bombino M, et al. Elevated plasma and alveolar levels of soluble receptor for advanced glycation endproducts are associated with severity of lung dysfunction in ARDS patients. Tohoku J Exp Med. 2010;222:105–12.CrossRefPubMed
18.
go back to reference Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000;165:2950–4.CrossRefPubMed Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000;165:2950–4.CrossRefPubMed
19.
go back to reference Phung TTB, Suzuki T, Phan PH, Kawachi S, Furuya H, Do HT, et al. Pathogen screening and prognostic factors in children with severe ARDS of pulmonary origin. Pediatr Pulmonol. 2017;52:1469–77.CrossRefPubMedPubMedCentral Phung TTB, Suzuki T, Phan PH, Kawachi S, Furuya H, Do HT, et al. Pathogen screening and prognostic factors in children with severe ARDS of pulmonary origin. Pediatr Pulmonol. 2017;52:1469–77.CrossRefPubMedPubMedCentral
Metadata
Title
Tuberculous pneumonia-induced severe ARDS complicated with DIC in a female child: a case of successful treatment
Authors
Dong Tien Ngo
Phuc Huu Phan
Shoji Kawachi
Noriko Nakajima
Naoyuki Hirata
Akira Ainai
Thuy Thi Bich Phung
Dien Minh Tran
Hai Thanh Le
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3215-5

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine